Table 1.
Baseline demographic characteristics (safety population).
| Baseline Characteristics | Placebo (n = 222) | Atogepant 10 mg QD (n = 221) | Atogepant30 mg QD (n = 228) | Atogepant 60 mg QD (n = 231) |
|---|---|---|---|---|
| Age, mean (SD), y | 40.3 (12.8) | 41.4 (12.1) | 42.1 (11.7) | 42.5 (12.4) |
| Female, n (%) | 198 (89.2) | 200 (90.5) | 204 (89.5) | 199 (86.1) |
| White, n (%) | 194 (87.4) | 181 (81.9) | 185 (81.1) | 192 (83.1) |
| Non-Hispanic, n (%) | 199 (89.6) | 200 (90.5) | 209 (91.7) | 217 (93.9) |
| BMI, mean (SD), kg/m2 | 30.8 (8.7) | 30.4 (7.6) | 31.2 (7.6) | 29.9 (7.3) |
BMI, body mass index; QD, once daily; SD, standard deviation.